Clinical Trial Update: Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PF-00885706 for relief of GERD symptoms was terminated, with a report on its efficacy and safety observations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• PF-00885706

Snippet

Sponsor: Pfizer | Conditions: Gastroesophageal Reflux Disease | Phase 2 | Status: TERMINATED